首页 > 市场调查报告书 > 医疗设备

市场调查报告书

商品编码

1683386

全球神经系统疾病数位治疗市场 - 2025 至 2033 年

Global Digital Therapeutics for Neurological Disorders Market - 2025-2033

出版日期: 2025年03月20日 | 出版商:

DataM Intelligence | 英文 166 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球神经系统疾病数位治疗市场规模达 2.4694 亿美元，预计到 2033 年将达到 5.0436 亿美元，2025-2033 年预测期内的复合年增长率为 8.3%。

神经系统疾病的数位疗法是指利用行动应用程式、软体程式、虚拟实境 (VR)、穿戴式装置和其他连接装置等数位平台来预防、管理或治疗神经系统疾病的实证治疗介入措施。这些治疗通常采用人工智慧 (AI)、机器学习 (ML)、巨量资料分析和神经刺激等先进技术，提供客製化、即时且通常非侵入性的护理。

数位疗法旨在提供精准、个人化和以患者为中心的干预，重点关注受神经系统疾病影响的认知、运动和行为功能。它们可以与传统治疗方法结合或作为独立疗法，可能涉及自我管理、復原、症状监测或行为矫正。这些数位解决方案旨在改善临床结果，同时与传统治疗相比提供更高的可近性、便利性和更低的成本。

市场动态：

驱动因素与约束因素

转向居家护理和远端病患监控

向家庭护理和远端病人监控的转变极大地推动了神经系统疾病数位治疗市场的成长，预计将在预测期内推动市场的发展。居家照护使患者无需频繁去医院即可接受治疗，这对于患有帕金森氏症、阿兹海默症或多发性硬化症等慢性神经系统疾病的患者尤其重要。透过数位疗法，患者可以使用行动应用程式、穿戴式装置或其他数位平台在家中管理他们的症状。

例如，Akili Interactive 的注意力不足过动症 (ADHD) 数位疗法 EndeavorRx 是一种可以在家使用的解决方案，患者无需到诊所就诊即可接受治疗，从而减轻了患者和医疗保健提供者的负担。

远端病人监控有助于克服地理障碍，使农村或服务不足地区的患者无需长途跋涉即可获得先进的神经系统护理。数位治疗解决方案（包括用于症状追踪和治疗依从性的应用程式）可以在任何地方使用，弥补获得专科护理方面的差距。

数位疗法旨在透过提供自我管理应用程式、提醒和个人化介入等工具来吸引患者。这提高了患者对治疗方案的依从性，特别是对于需要长期治疗的慢性神经系统疾病患者。许多数位解决方案的互动性和游戏化特性增强了参与度，使患者更容易坚持规定的治疗方案并定期追踪他们的进展。

例如，2023 年 10 月，BeCareLink 推出了一款新的定量和人工智慧 (AI) 应用程序，以支援一般神经系统检查，以筛选和监测神经系统疾病。这款名为 BeCare Neuro Link 的新行动应用程式旨在对神经系统疾病患者或患有潜在神经系统疾病的患者进行远端、客观和全面的评估。

资料隐私和网路安全问题

资料隐私和网路安全是神经系统疾病数位治疗市场的主要关注点，因为这些平台依赖敏感患者资料的收集、储存和分析，包括个人健康资讯 (PHI)、认知评估和即时健康监测。数位治疗平台通常将患者资料储存在基于云端的系统或其他线上基础设施中，这使得它们容易受到网路攻击。敏感健康资料的洩漏可能导致身分盗窃、金融诈欺甚至医疗诈欺。

例如，根据《HIPAA杂誌》报导，2023 年 8 月，人们发现有 2,300 万份医疗记录被洩露。在过去的 12 个月中，平均每月有 9,989,003 份医疗记录被洩露。截至 2024 年 8 月 31 日的一年中，已发生 491 起涉及 500 条或更多记录的资料外洩事件，已知洩漏的记录至少有 58,668,002 则。 2024 年的平均洩漏记录规模目前为 119,487 笔记录，中位洩漏记录规模为 4,109 笔记录。

市场领导者和先驱者
- 新兴先锋和杰出参与者
- 拥有最大销售品牌的既定领导者
- 拥有成熟产品的市场领导者
CXO 观点
最新进展与突破
案例研究/正在进行的研究
监管和报销情况
- 北美洲
- 欧洲
- 亚太地区
- 拉丁美洲
- 中东和非洲
波特五力分析
供应链分析
专利分析
SWOT 分析
未满足的需求和差距
市场进入和扩张的推荐策略
情境分析：最佳情况、基本情况和最坏情况预测
定价分析和价格动态
关键意见领袖

第 5 章：神经系统疾病数位治疗市场（依产品类型）

软体治疗学
穿戴式装置

第 6 章：神经系统疾病数位治疗市场（依疾病类型）

神经退化性疾病
- 阿兹海默症
- 帕金森氏症
- 多发性硬化症
- 亨丁顿舞蹈症
- 其他的
精神健康障碍
- 沮丧
- 焦虑
- 创伤后压力症候群
- 躁郁症
- 强迫症 (OCD)
- 其他的
中风和脑血管疾病
睡眠障碍
- 失眠
- 睡眠呼吸中止症
- 其他的
认知障碍
其他的

第 7 章：神经系统疾病数位治疗市场（按最终用户划分）

医院
专科诊所
神经復健中心
家庭护理设置
其他的

第 8 章：神经系统疾病数位治疗市场，按区域市场分析和成长机会

北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 欧洲其他地区
拉丁美洲
- 墨西哥
- 巴西
- 阿根廷
- 拉丁美洲其他地区
亚太
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
中东和非洲

第九章：竞争格局与市场定位

竞争概况和主要市场参与者
市占率分析与定位矩阵
策略伙伴关係、併购
产品组合和创新的关键发展
公司基准化分析

第十章：公司简介

Akili, Inc.

公司概况
产品组合
- 产品描述
- 产品关键绩效指标 (KPI)
- 历史和预测产品销售量
- 产品销售量
财务概览
- 公司收入
- 地区收入份额
- 收入预测
主要进展
- 合併与收购
- 关键产品开发活动
- 监管部门批准等
SWOT 分析

Click Therapeutics, Inc.
BigHealth
Apple Inc.
MindMaze Inc
NeuroPace, Inc.
NeurologyToolKit
Matoph Labs eU
Fullpower Technologies, Inc.
Neybox Digital Ltd.

第 11 章：假设与研究方法

资料收集方法
数据三角测量
预测技术
数据验证和确认

第 12 章：附录

简介目录

Product Code: HCIT9333

The global digital therapeutics for neurological disorders market reached US$ 246.94 million in 2024 and is expected to reach US$ 504.36 million by 2033, growing at a CAGR of 8.3% during the forecast period 2025-2033.

Digital therapeutics for neurological disorders refer to evidence-based therapeutic interventions that leverage digital platforms such as mobile apps, software programs, virtual reality (VR), wearables and other connected devices to prevent, manage or treat neurological conditions. These treatments are often powered by advanced technologies such as artificial intelligence (AI), machine learning (ML), big data analytics and neurostimulation to deliver tailored, real-time and often non-invasive care.

Digital therapeutics are designed to provide precise, personalized and patient-centered interventions, focusing on cognitive, motor and behavioral functions that are impacted by neurological disorders. They can be used in conjunction with traditional treatments or as standalone therapies and may involve self-management, rehabilitation, symptom monitoring or behavior modification. These digital solutions aim to improve clinical outcomes while offering greater accessibility, convenience and reduced costs compared to traditional treatments.

Market Dynamics: Drivers & Restraints

Shift Towards Home-Based Care & Remote Patient Monitoring

The shift towards home-based care & remote patient monitoring is significantly driving the growth of the digital therapeutics for neurological disorders market and is expected to drive the market over the forecast period. Home-based care allows patients to receive treatment without the need for frequent hospital visits, particularly important for patients with chronic neurological conditions like Parkinson's Disease, Alzheimer's or Multiple Sclerosis. By leveraging digital therapeutics, patients can manage their symptoms at home using mobile apps, wearables or other digital platforms.

For instance, Akili Interactive's EndeavorRx, a digital therapeutic for ADHD, is an example of a solution that can be used at home, allowing patients to receive therapy without the need for in-clinic visits, reducing the burden on both patients and healthcare providers.

Remote patient monitoring helps overcome geographic barriers, allowing patients in rural or underserved areas to access advanced neurological care without traveling long distances. Digital therapeutics solutions, which include apps for symptom tracking and therapy adherence, can be used anywhere, bridging gaps in access to specialized care.

Digital therapeutics are designed to engage patients by offering tools like self-management apps, reminders, and personalized interventions. This improves patient adherence to therapy regimens, especially in chronic neurological conditions that require long-term management. The interactive and gamified nature of many digital solutions boosts engagement, making it easier for patients to stick with prescribed therapy regimens and track their progress regularly.

For instance, in October 2023, BeCareLink introduced a new quantitative and artificial intelligence (AI)-enabled app to support general neurologic exams for the screening and monitoring of neurologic diseases. Called BeCare Neuro Link, the new mobile application is intended for the remote, objective and comprehensive assessment of neurologic patients or those with potential neurologic conditions.

Data Privacy & Cybersecurity Concerns

Data privacy and cybersecurity are major concerns in the digital therapeutics for neurological disorders market, as these platforms rely on the collection, storage and analysis of sensitive patient data, including personal health information (PHI), cognitive assessments, and real-time health monitoring. Digital therapeutics platforms often store patient data in cloud-based systems or other online infrastructures, making them vulnerable to cyberattacks. A breach of sensitive health data could result in identity theft, financial fraud, or even medical fraud.

For instance, according to the HIPAA Journal, in August 2023, 23 million breached healthcare records are noticed. Over the past 12 months, an average of 9,989,003 healthcare records were breached each month. In the year to August 31, 2024, there have been 491 data breaches of 500 or more records, and at least 58,668,002 records are known to have been breached. The average breach size in 2024 is currently 119,487 records and the median breach size is 4,109 records.

Segment Analysis

The global digital therapeutics for neurological disorders market is segmented based on product type, disease type, end-user and region.

Product Type:

The software therapeutics from the product type segment are expected to dominate the global digital therapeutics for neurological disorders market

Software therapeutics, primarily through mobile applications and web-based platforms, are accessible anytime, anywhere, making them a convenient option for patients. This ease of use is a major reason why software-based digital therapeutics are preferred in home-based care scenarios, especially for neurological conditions where ongoing management is required.

For instance, Cogstate's Cognigram is a software platform that provides cognitive testing for people with Alzheimer's disease and mild cognitive impairment. This platform enables patients to track cognitive performance remotely and interact with their healthcare provider, offering a more convenient and accessible solution than traditional in-clinic testing.

Software therapeutics are generally more cost-effective compared to traditional treatments that involve frequent doctor visits, hospitalizations, or long-term medication. By offering at-home solutions and reducing the need for in-person consultations, software therapeutics can lower the overall healthcare costs for both patients and healthcare providers. For instance, Pear Therapeutics' reSET-O, a prescription digital therapeutic for opioid use disorder, is an FDA-approved software solution that reduces the need for continuous in-person visits and provides remote support.

Geographical Analysis

North America is expected to hold a significant position in the global digital therapeutics for neurological disorders market

North America, and particularly the United States, benefits from a well-established regulatory framework through the FDA (Food and Drug Administration), which has streamlined the approval process for digital therapeutics. This regulatory clarity boosts market confidence and accelerates the adoption of digital therapeutics solutions for neurological disorders. For instance, The FDA's Digital Health Innovation Action Plan aims to promote innovation and expedite the approval of digital therapeutics. The approval of products like EndeavorRx (for ADHD) and reSET (for addiction treatment) demonstrates the regulatory readiness in North America to approve digital solutions for treating neurological conditions.

The prevalence of neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy is rising in North America, driving the demand for digital therapeutics. The aging population in the United States and Canada is a major factor contributing to this increase. The number of people diagnosed with Alzheimer's is expected to grow significantly in North America due to the aging Baby Boomer population.

Digital therapeutic platforms that provide cognitive training, symptom tracking, and remote monitoring are increasingly sought after to manage the long-term care needs of these patients. For instance, according to the Alzheimer's Association, in the U.S. alone, 5.8 million people were living with Alzheimer's disease in 2020, and that number is expected to double by 2060. As the number of patients increases, so does the demand for digital health solutions to manage these conditions.

Competitive Landscape

The major global players in the digital therapeutics for neurological disorders market include Akili, Inc., Click Therapeutics, Inc., BigHealth, Apple Inc., MindMaze Inc, NeuroPace, Inc., NeurologyToolKit, Matoph Labs e.U., Fullpower Technologies, Inc., Neybox Digital Ltd. and among others.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global digital therapeutics for neurological disorders market report delivers a detailed analysis with 62 key tables, more than 56 visually impactful figures and 166 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Market Introduction and Scope

1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope

2. Executive Insights and Key Takeaways

2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Disease Type
2.5. Snippet by End-User
2.6. Snippet by Region

3. Dynamics

3.1. Impacting Factors
- 3.1.1. Drivers
  - 3.1.1.1. Shift Towards Home-Based Care & Remote Patient Monitoring
  - 3.1.1.2. Rising Prevalence of Neurological Disorders
- 3.1.2. Restraints
  - 3.1.2.1. Data Privacy & Cybersecurity Concerns
  - 3.1.2.2. Patient Adherence & Engagement Challenges
- 3.1.3. Opportunity
  - 3.1.3.1. Rising Technological Advancements
- 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

4.1. Market Leaders and Pioneers
- 4.1.1. Emerging Pioneers and Prominent Players
- 4.1.2. Established Leaders with Largest Selling Brand
- 4.1.3. Market Leaders with Established Product
4.2. CXO Perspectives
4.3. Latest Developments and Breakthroughs
4.4. Case Studies/Ongoing Research
4.5. Regulatory and Reimbursement Landscape
- 4.5.1. North America
- 4.5.2. Europe
- 4.5.3. Asia Pacific
- 4.5.4. Latin America
- 4.5.5. Middle East & Africa
4.6. Porter's Five Force Analysis
4.7. Supply Chain Analysis
4.8. Patent Analysis
4.9. SWOT Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders

5. Digital Therapeutics for Neurological Disorders Market, By Product Type

5.1. Introduction
- 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 5.1.2. Market Attractiveness Index, By Product Type
5.2. Software Therapeutics*
- 5.2.1. Introduction
- 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Wearable Devices

6. Digital Therapeutics for Neurological Disorders Market, By Disease Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 6.1.2. Market Attractiveness Index, By Disease Type
6.2. Neurodegenerative Disorders*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.2.3. Alzheimer's Disease
- 6.2.4. Parkinson's Disease
- 6.2.5. Multiple Sclerosis
- 6.2.6. Huntington's Disease
- 6.2.7. Others
6.3. Mental Health Disorders
- 6.3.1. Depression
- 6.3.2. Anxiety
- 6.3.3. Post-Traumatic Stress Disorder
- 6.3.4. Bipolar Disorder
- 6.3.5. Obsessive-Compulsive Disorder (OCD)
- 6.3.6. Others
6.4. Stroke & Cerebrovascular Disorders
6.5. Sleep Disorders
- 6.5.1. Insomnia
- 6.5.2. Sleep Apnea
- 6.5.3. Others
6.6. Cognitive Disorders
6.7. Others

7. Digital Therapeutics for Neurological Disorders Market, By End-User

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Specialty Clinics
7.4. Neuro-Rehabilitation Centers
7.5. Homecare Settings
7.6. Others

8. Digital Therapeutics for Neurological Disorders Market, By Regional Market Analysis and Growth Opportunities

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 8.1.2. Market Attractiveness Index, By Region
8.2. North America
- 8.2.1. Introduction
- 8.2.2. Key Region-Specific Dynamics
- 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.2.6.1. U.S.
  - 8.2.6.2. Canada
8.3. Europe
- 8.3.1. Introduction
- 8.3.2. Key Region-Specific Dynamics
- 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.3.6.1. Germany
  - 8.3.6.2. U.K.
  - 8.3.6.3. France
  - 8.3.6.4. Spain
  - 8.3.6.5. Italy
  - 8.3.6.6. Rest of Europe
8.4. Latin America
- 8.4.1. Introduction
- 8.4.2. Key Region-Specific Dynamics
- 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.4.6.1. Mexico
  - 8.4.6.2. Brazil
  - 8.4.6.3. Argentina
  - 8.4.6.4. Rest of Latin America
8.5. Asia-Pacific
- 8.5.1. Introduction
- 8.5.2. Key Region-Specific Dynamics
- 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.5.6.1. China
  - 8.5.6.2. India
  - 8.5.6.3. Japan
  - 8.5.6.4. South Korea
  - 8.5.6.5. Rest of Asia-Pacific
8.6. Middle East and Africa
- 8.6.1. Introduction
- 8.6.2. Key Region-Specific Dynamics
- 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking

10. Company Profiles

10.1. Akili, Inc.*
- 10.1.1. Company Overview
- 10.1.2. Product Portfolio
  - 10.1.2.1. Product Description
  - 10.1.2.2. Product Key Performance Indicators (KPIs)
  - 10.1.2.3. Historic and Forecasted Product Sales
  - 10.1.2.4. Product Sales Volume
- 10.1.3. Financial Overview
  - 10.1.3.1. Company Revenue's
  - 10.1.3.2. Geographical Revenue Shares
  - 10.1.3.3. Revenue Forecasts
- 10.1.4. Key Developments
  - 10.1.4.1. Mergers & Acquisitions
  - 10.1.4.2. Key Product Development Activities
  - 10.1.4.3. Regulatory Approvals, etc.
- 10.1.5. SWOT Analysis
10.2. Click Therapeutics, Inc.
10.3. BigHealth
10.4. Apple Inc.
10.5. MindMaze Inc
10.6. NeuroPace, Inc.
10.7. NeurologyToolKit
10.8. Matoph Labs e.U.
10.9. Fullpower Technologies, Inc.
10.10. Neybox Digital Ltd.